Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%
Journal of Neuroendocrinology · 2026-01 · 38 (1)
DOI: 10.1111/jne.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 15.11.2025. Verfasst von Johanna Braegelmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatostatin, Ki-67 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood. This study aimed to investigate the outcomes of SSA therapy in differentiated NETs with a Ki‐67 index of ≥10%. A retrospective analysis of a prospectively created dataset of consecutive patients with NETs was performed. Patients with first‐line SSA monotherapy in advanced NET with a Ki‐67 index ≥10% were included. The study endpoints were progression‐free survival (PFS), overall survival (OS), and clinical benefit rate, defined as partial remission (PR) or stable disease (SD). Of 362 consecutive patients with a Ki‐67 index ≥10%, 67 received first‐line SSA therapy. The Ki‐67 index was 10–20% (G2) in 57 (85%) patients and >20% (G3) in 10 (15%). SD as the best response was reached in 40 (59.7%) patients and PR in 3 (4.5%), irrespective of the NET origin, time from the diagnosis, or somatostatin receptor‐based tracer uptake. The median PFS was 18 (95% confidence interval [CI], 5.7–30.3) months, and the median OS was 60 (95% CI, 38.2–81.8) months after the initiation of SSA therapy. Median PFS was significantly longer in patients with a Ki‐67 index of 10–20% (19 months; 95% CI, 6.2–31.8) compared to those with G3 NETs (6 months; 95% CI, 2.9–9.1; p = .015, log‐rank test), and in patients with a liver tumor burden of ≤10% (24 months; 95% CI, 12.7–35.3) versus >10% (4 months; 95% CI, 2.3–5.7; p = .007). First‐line SSA therapy can provide meaningful disease control in patients with G2 NETs and low tumor burden, despite a Ki‐67 index ≥10%. It may be a reasonable alternative to more intensive therapies in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, Essen, Germany.
- Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
- Institute for Artificial Intelligence in Medicine (IKIM), University Hospital Essen (AöR), Essen, Germany.
ORCID-Profile: Johanna Braegelmann
Zitieren
APA
Braegelmann, J., Mathew, A., Schmidt, B., Kalisch, H., Fendler, W. P., Führer-Sakel, D., & Lahner, H. (2026). Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%. Journal of Neuroendocrinology, 38(1). https://doi.org/10.1111/jne.70112
Vancouver
Braegelmann J, Mathew A, Schmidt B, Kalisch H, Fendler WP, Führer-Sakel D, et al. Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%. Journal of Neuroendocrinology. 2026;38(1). doi:10.1111/jne.70112
BibTeX
@article{Braegelmann2026,
author = {Braegelmann, Johanna and Mathew, Annie and Schmidt, Boerge and Kalisch, Hamza and Fendler, Wolfgang P and Führer-Sakel, Dagmar and Lahner, Harald},
title = {Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {1},
doi = {10.1111/jne.70112}
}
EUVIMED